Indications / Non-small cell lung cancer · Breast cancer · Pancreatic cancer · Colorectal cancer · Acute myeloid leukemia · Chronic myeloid leukemia · Multiple myeloma · Glioblastoma · Glioma · Neuroblastoma · Medulloblastoma · Diffuse midline glioma (DIPG) · Ependymoma · Atypical teratoid rhabdoid tumour (AT/RT) · Childhood acute lymphoblastic leukemia · Ewing sarcoma · Osteosarcoma · Rhabdomyosarcoma
Acute myeloid leukemia
Menin inhibitors, FLT3 and IDH combinations, venetoclax backbones and what comes after.
ASH Annual Meeting 2026
12–15 Dec 2026, New Orleans · Blood 148 (Supplement 1)
The meeting is in December. Regular abstracts have been public since 4 Nov 2026 but the Blood supplement was not in Crossref on 11 Nov, so ASH abstracts here come from web research. Late-breaking abstracts are embargoed until 7 Dec and are not shown.
Headline and verified abstracts
16 abstracts found by Parallel web research on 2026-11-11 and verified: 16 checked on the source page. Rows that could not be verified were dropped. Titles and metadata only; abstract text is not stored.
- 228Oral presentation
- 386Oral presentation
- 388Oral presentationRevumenib as pre-emptive therapy for measurable residual disease in NPM1 mutated or KMT2A-rearranged AML: Update from the ALLG AMLM26 intercept platform trialALLG AMLM26 interceptrevumenibVerified on source pageonlineprogram.hematology.org
- 502Oral presentationMeasurable residual disease detection by RT-qPCR for pediatric acute myeloid leukemiaAnushka Walia, MDVerified on source pageonlineprogram.hematology.org
- 661Oral presentation
- 662Oral presentationAzacitidine, venetoclax, and revumenib in newly diagnosed NPM1-mutated (NPM1m) or KMT2A-rearranged (KMT2Ar) acute myeloid leukemia (AML): Final analysis of beat AML phase 1b studyJoshua F. Zeidner, MDbeat AMLazacitidinevenetoclaxrevumenibVerified on source pageonlineprogram.hematology.org
- 901Oral presentation
- 906Oral presentationUpdated results from cladribine, idarubicin, and cytarabine (CLIA) in combination with venetoclax in younger newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome: A phase II studyFieke W Hoff, MD, PhDCLIAcladribineidarubicincytarabinevenetoclaxVerified on source pageonlineprogram.hematology.org
- 1012Oral presentationVenetoclax plus three-day multi-frequency decitabine (DEC3-VEN) versus azacitidine plus venetoclaxDEC3-VENvenetoclaxdecitabineazacitidineVerified on source pageonlineprogram.hematology.org
- 1637Poster
- 1642PosterIvosidenib + azacitidine in newly diagnosed mIDH1 AML: The ongoing ALIDHE study confirms efficacy and safety in clinical practiceALIDHEivosidenibazacitidineVerified on source pageonlineprogram.hematology.org
- 1645PosterFLAG-ida, venetoclax, and FLT3 inhibitor combination therapy in newly diagnosed FLT3-mutated AML: High CR/CRi rates including in ELN adverse-risk diseaseFLAG-idavenetoclaxFLT3 inhibitorVerified on source pageonlineprogram.hematology.org
- 1647PosterVenetoclax, azacitidine, and homoharringtonine (VAH) in newly diagnosed acute myeloid leukemia: A propensity score-matched comparison with VA and IA regimensVAHvenetoclaxazacitidinehomoharringtonineVerified on source pageonlineprogram.hematology.org
- 1653PosterVenetoclax and azacitidine with or without idarubicin in fit newly diagnosed AML: A real-world risk-adapted study of 165 casesvenetoclaxazacitidineidarubicinVerified on source pageonlineprogram.hematology.org
- 1655PosterA safety run-in of decitabine/cedazuridine, venetoclax, and enasidenib for newly diagnosed IDH2-mutated AML: The myelomatch MM1OA-S03 studymyelomatch MM1OA-S03decitabine/cedazuridinevenetoclaxenasidenibVerified on source pageonlineprogram.hematology.org
- 1OtherSuperior event-free survival with ivosidenib plus intensive chemotherapy in newly diagnosed IDH1-mutated AML: Results from the phase 3 HOVON150/AMLSG29-18 trialBas J Wouters, MD, PhDHOVON150/AMLSG29-18ivosidenibcytarabinedaunorubicinmitoxantroneVerified on source pageonlineprogram.hematology.org
Indexed in Crossref
The ASH Annual Meeting 2026 supplement (Blood 148 (Supplement 1)) was not in Crossref when last checked on 11 Nov 2026. The verified abstracts above come from web research instead.